加味麦门冬汤联合安罗替尼治疗晚期驱动基因阴性非小细胞肺癌临床疗效OACSTPCD

Objective:To explore the clinical efficacy of modified Maimendong decoction combined with anlotinib in the treatment of advanced driver gene-negative non-small cell lung cancer(NSLC)of qi and yin deficiency.Methods:The clinical data of patients with advanced driver gene-negative NSLC of qi and yin deficiency type were retrospectively analyzed.They were divided into observation group(n=57)and control group(n=55)according to whether they were treated with Maimendong decoction or not.The clinical efficacy and occurrence of adverse reactions,TCM syn-dromes scores,serum tumor markers[carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA-21),car-bohydrate antigen 125(CA125)],disease-related biochemical indicators[vascular endothelial growth factor(VEGF),platelet-derived growth factor(PDGF)]and quality of life[Karnofsky Performance Status(KPS)]before treatment and after 3 courses of treatment and survival status after 1 year of treatment were compared between both groups of patients.Results:After 3 courses of treatment,the clinical effective rate and KPS score in observation group were significantly higher than those in control group(all P<0.05),while the levels of serum tumor markers and dis-ease-related biochemical indicators were significantly lower than those in control group(all P<0.05).The survival rate in observation group after 1 year of treatment was higher than that in control group(P<0.05).There were no significant differences in adverse reactions between the two groups(P>0.05).Conclusion:Modified Maimendong de-coction combined with anlotinib can improve the syndrome of qi and yin deficiency of advanced driver gene negative NSLC patients,reduce the level of serum tumor markers,inhibit tumor cell metastasis,improve the quality of life of patients,and have fewer adverse reactions.